NCT01758887

Brief Summary

  • Would be there any difference in dopamine synthesis between remitted clinical high risk subjects for psychosis and healthy control?
  • What would happen to dopamine synthesis after antipsychotic discontinuation in clinical high risk subjects for psychosis?
  • What about the dopamine synthesis in recurred clinical high risk subjects for psychosis after the discontinuation?

Trial Health

30
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Timeline
Completed

Started Dec 2012

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
withdrawn

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

December 1, 2012

Completed
26 days until next milestone

First Submitted

Initial submission to the registry

December 27, 2012

Completed
5 days until next milestone

First Posted

Study publicly available on registry

January 1, 2013

Completed
3.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2016

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2016

Completed
Last Updated

October 13, 2016

Status Verified

October 1, 2016

Enrollment Period

3.8 years

First QC Date

December 27, 2012

Last Update Submit

October 12, 2016

Conditions

Outcome Measures

Primary Outcomes (1)

  • Presynaptic dopamine synthesis in the striatum

    measured with \[18F\]DOPA positron emission tomography

    baseline

Study Arms (2)

Controls

Healthy control

patients

clinical high risk subjects for psychosis

Eligibility Criteria

Age16 Years - 40 Years
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17), Adult (18-64)
Sampling MethodNon-Probability Sample
Study Population

Clinical high risk subjects for psychosis who have been treated with antipsychotic medication so that reach to the remission.

You may qualify if:

  • Diagnosed as a clinical High Risk
  • Treated with antipsychotic drugs
  • PSP1-5 (from SIPS criteria) \<3 (severity index)for more than 6 months
  • Had not experienced a symptomatic relapse in the 6 months

You may not qualify if:

  • Significant abnormality in laboratory tests
  • History of head trauma

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Seoul National University Hospital

Seoul, 110-744, South Korea

Location

MeSH Terms

Conditions

Schizophrenia

Condition Hierarchy (Ancestors)

Schizophrenia Spectrum and Other Psychotic DisordersMental Disorders

Study Officials

  • Jun Soo Kwon, MD PhD

    Seoul National University College of Medicine

    PRINCIPAL INVESTIGATOR
0

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

December 27, 2012

First Posted

January 1, 2013

Study Start

December 1, 2012

Primary Completion

September 1, 2016

Study Completion

September 1, 2016

Last Updated

October 13, 2016

Record last verified: 2016-10

Data Sharing

IPD Sharing
Will not share

Locations